Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Returns
Return on equity-28.3%
Return on assets-26.8%
Return on invested capital-38.2%
Liquidity
Current ratio27.1×+0.9×26.2×-10.2×36.4×+13.6×22.7×-8.3×31×
Quick ratio27.1×+0.9×26.2×-10.2×36.4×+13.6×22.7×-8.3×31×
Cash ratio4.4×+1.6×2.8×-14.8×17.6×+12.9×4.6×-1.5×6.1×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×
Per Share
Book value per share$9.98-19.8%$12.45-7.7%$13.49+81.4%$7.43-8.3%$8.11-45.0%
Valuation
Market capitalization$1.5B+3.4%$1.45B+5.6%$1.37B+203%$451.84M+23.4%$366.06M
Enterprise value$1.43B+1.7%$1.4B+24.3%$1.13B+177%$408.64M+29.2%$316.3M
Price / book3.2×+0.2×+0.3×2.7×+1.0×1.7×+0.4×1.3×
Free cash flow yield-5.4%+0.7pp-6.1%-0.4pp-5.7%+11.3pp-17%+1.9pp-18.9%
Earnings yield-7.2%+0.5pp-7.7%-0.6pp-7.1%+12.4pp-19.5%+2.2pp-21.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Rapport Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Rapport Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.